Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy

British Journal of Cancer

Volumn 74, Issue 3, 1996, Pages 474-478

  MacCallum, J ^a,b   Keen, J C ^b   Bartlett, J M S ^c   Thompson, A M ^a   Dixon, J M ^a   Miller, W R ^b  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Tamoxifen; Transforming growth factor beta

Indexed keywords

ESTROGEN RECEPTOR; MESSENGER RNA; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS; ULTRASOUND;

EID: 0030036656     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.385     Document Type: Article

References (51)

1. ANDERSON ADC, FORREST APM, LEVACK PA, CHETTY U AND HAWKINS RA. (1989). Response to endocrine manipulation and oestrogen receptor concentration in larger operable primary breast cancer. Br. J. Cancer, 60, 223-226.
2. ARRICK BA, KORE MA, DERYNCK R. (1990). Differential regulation of expression of three transforming growth factor β species in human breast cancer cell lines by estradiol. Cancer Res., 50, 299-303.
3. ARRICK BA, LOPEZ AR, ELFMAN F, EBNER R, DAMSKY CH AND DERYNCK R. (1992). Altered metabolic and adhesive properties and increased tumorigenicity associated with increased expression of transforming growth factor β1. J. Cell. Biol., 118, 715-726.
4. ARTEAGA CL, HURD SD, WINNIER AR, JOHNSON MD, FENDLY BM AND FORBES JT. (1993). Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. J. Clin. Invest., 92, 2569-2576.
5. AUFFREY C AND ROUGEON F. (1980). Purification of mouse immunoglobulin heavy chain mRNA from total myeloma tumour RNA. Eur. J. Biochem., 107, 303.
6. AUVINEN P, LIPPONEN P, JOHANSSON R AND SYRJÄNEN K. (1995). Prognostic significance of TGF-β2 expression in female breast cancer. Eur. J. Cancer, 31A, 851.
7. BARTLETT JMS, RABIASZ GJ, SCOTT WN, LANGDON SP, SMYTH JP AND MILLER WR. (1992). Transforming growth factor-β mRNA expression and growth control of human ovarian carcinoma cells. Br. J. Cancer, 65, 655-660.
8. BARRETT-LEE PJ, TRAVERS M, LUQMANI Y AND COOMBES RC. (1990). Transcripts for transforming growth factors in human breast cancer: clinical correlates. Br. J. Cancer, 65, 655-660.
9. BERTHOIS Y, KATZENELLENBOGEN JA AND KATZENELLENBOGEN BS. (1986). Phenol red in tissue culture media is a weak oestrogen: impacts concerning the study of oestrogen-responsive cells in culture. Proc. Natl. Acad. Sci, USA, 83, 2496-2500.
10. BUTTA, A MACLENNAN K, FLANDERS KC, SACKS NPM, SMITH I, MCKINNA A, DOWSETT M, WAKEFIELD LM, SPORN MB, BAUM M AND COLLETTA AA. (1992). Induction of transforming growth factor β1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res., 52, 4261-4264.
11. CHANG, H-L, GILLET N, FIGARI I, LOPEZ AR, PALLADION MA AND DERYNCK R. (1993). Increased transforming growth factor β expression inhibits cell proliferation in vitro, yet increases tumorigenicity and tumour growth of meth A sarcoma cells. Cancer Res., 53, 4391-4398.
12. COLLETTA AA. (1990). The transforming growth factors beta - their potential in the treatment and chemoprevention of cancer. Cancer Topics, 8, 18-19.
13. COLLETTA AA, WAKEFIELD LM, HOWELL FV, DANIELPOUR D, BAUM M AND SPORN MB. (1991). The growth inhibition of human breast cancer cells by novel synthetic progestin involves the induction of transforming growth factor beta. J. Clin. Invest., 87, 277-283.
14. COLETTA AA, BENSON JR AND BAUM M. (1994). Alternative mechanisms of action of anti-oestrogens. Breast Cancer Res. Treat., 31, 5-9.
15. DICKSON RB, KASID A, HUFF KK, BATES SE, KNABBE C, BRONZERT D, GELMAN EP AND LIPPMAN ME. (1987). Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17β-estradiol or v-Ha-ras oncogene. Proc. Natl Acad. Sci. USA, 84, 837-841.
16. DUBLIN EA, BARNES DM, WANG DY, KING RJB AND LEVISON DA. (1993). TGF-alpha and TGF-beta expression in mammary carcinoma. J. Pathol., 170, 15-22.
17. FOROUHI P, WALSH JS, ANDERSON TJ AND CHETTY U. (1994). Ultrasonography as a method of measuring breast tumour size and monitoring response to primary systemic therapy. Br. J. Surg., 81, 223-225.
18. GORSCH SM, MEMOLI V, STUKEL TA, GOLD LI AND ARRICK BA. (1992). Immunohistochemical staining for transforming growth factor βl associates with disease progression in human breast cancer. Cancer Res., 52, 6949-6952.
19. JAKOWLEW SB, CUBERT J, DANIELPOUR D, SPORN MB AND ROBERTS AB. (1992). Differential regulation of the expression of transforming growth factor-β mRNAs by growth factors and retinoic acid in chicken embryo chondrocytes, myocytes and fibroblasts. J. Cell. Physiol., 150, 377-385.
20. JENG, M-H, TEN DIJKE P, IWATA KK AND JORDAN VC. (1993). Regulation of the levels of three transforming growth factor β mRNAs by oestrogen and their effects on the proliferation of human breast cancer cells. Mol. Cell. Endocrinol, 97, 115-123.
21. JHALA N, BALSARA G, ALBO D, GRANICK M, GOLD L, ATKINSON BF AND SOLOMON M. (1995). Transforming growth factor-β (TGFβ) isoform reactivity in normal and neoplastic breast tissue. Lab. Invest., 72, A19.
22. JI, H-J, STOUT LE, ZHANG QQ, ZHANG RP, LEUNG HT AND LEUNG BS. (1994). Absence of transforming growth factor beta response in the tamoxifen growth-inhibited human breast cancer cell line cama-1. J. Cell. Biochem., 54, 332-342.
23. JORDAN VC. (1993). Growth factor regulation by tamoxifen is demonstrated in patients with breast cancer. Cancer, 72, 1-2.
24. KATZENELLENBOGEN JA, CARLSON KE, HEIMAN DF, ROBERTSON DW, WEI LL AND KATZENELLENBOGEN BS. (1983). Efficient and selective covalent labelling of the oestrogen receptor with [H-3]-labelled tamoxifen aziridine. J. Biol. Chem., 258, 3487-3495.
25. KERBEL R. (1992). Expression of multicytokine and multigrowth factor independence in advanced stage metastatic cancer-malignant melanoma as a paradigm. Am. J. Pathol., 141, 519-524.
26. KERBEL RS. (1993). Growth factors as mediators of malignant progression. Cancer Metast. Rev., 12, 215-217.
27. KING RJB, WANG DY, DALY RJ AND DARBRE PD. (1989). Approaches to studying the role of growth factors in the progression of breast tumours from steroid sensitive to insensitive state. J. Steroid Biochem., 34, 133-138.
28. KNABBE C, LIPPMAN ME, WAKEFIELD LM, FLANDERS KC, KASID A, DERYNCK R AND DICKSON RB. (1987). Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell, 48, 417-428.
29. KNABBE C, ZUGMAIER G, SCHMAHL M, DIETEL M, LIPPMAN ME AND DICKSON RB. (1991). Induction of transforming growth factor β by the antioestrogens droloxifene, tamoxifen and toremifene in MCF-7 cells. Am. J. Clin. Oncol., 14, S15-S20.
30. LAFYATIS R, LECHLEIDER R, KIM SJ, JAKOWLEW S, ROBERTS AB AND SPORN MB. (1990). Structural and functional characterization of the transforming growth factor β3 promoter: a cAMP response element regulates basal and induced transcription. J. Biol. Chem., 265, 19128-19136.
31. LIPPMAN ME, DICKSON RB, GELMANN EP, ROSEN N, KNABBE C, BATES S, BRONZERT D, HUFF K AND KASID A. (1987). Growth regulation of human breast carcinoma occurs through regulated growth factor secretion. J. Cell. Biochem., 35, 1-16.
32. MACCALLUM J, BARTLETT JMS, THOMPSON AM, KEEN JC, DIXON JM AND MILLER WR. (1994). Expression of transforming growth factor beta mRNA isoforms in human breast cancer. Br. J. Cancer, 69, 1006-1009.
33. MACCALLUM J, POULSOM R, HANBY AM AND MILLER WR. (1995). Expression and distribution of TGFβ mRNA isoforms in a small group of human breast cancers examined by in situ hybridisation. The Breast, 4, 289-296.
34. MCCUNE BK, MULLIN BR, FLANDERS KC, JAFFURS WJ, MULLEN LT AND SPORN MB. (1992). Localization of transforming growth factor-β isotypes in lesions of the human breast. Hum. Pathol., 23, 13-20.
35. MANNING AM, WILLIAMS HC, GAME SM AND PARASKEVA C. (1991). Differential sensitivity of human colonic adenocarcinoma and carcinoma cells to transforming-growth factor-beta (tgf-beta) - conversion of an adenoma cell-line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitor effects of tgf-beta. Oncogene, 6, 1471-1476.
36. MIZUKAMI Y, TAJIRI K, NONOMURA A, NOGUCHI M, TANIYA T, KOYASAKI N, NAKAMURA S AND MATSUBARA F. (1991). Effects of tamoxifen, medroxyprogesterone acetate and estradiol on tumour growth and oncogene expression in MCF-7 breast cancer cell line transplanted into nude mice. Anticancer Res., 11, 1333-1338.
37. MOSES HL, TUCKER RF, LOEF EB, COFFEY, RJ JR, HALPER J AND SHIPLEY GD. (1985). Type beta transforming growth factor is a growth stimulator and a growth inhibitor. Cancer Cells, 3, 65-71.
38. 1 on in vitro angiogenesis. Exp. Cell. Res., 204, 356-363.
39. PIERCE DE, GORSKA AE, CHYTIL A, MEISE KS, PAGE DL, COFFEY RJ AND MOSES HL. (1995). Mammary tumour suppression by transforming growth factor β1 transgene expression. Proc. Natl. Acad. Sci., USA, 92, 4254-4258.
40. ROBERTS AB, ANZANO MA, WAKEFIELD LM, ROCHE NS, STERN DF AND SPORN MB. (1985). Type β transforming growth factor: A bifunctional regulator of cellular growth. Proc. Natl. Acad. Sci. USA, 82, 119-123.
41. SALOMON DS, CIARDIELLO F, VALVERIUS E, SAEKI T AND KIM N. (1989). Transforming growth factors in human breast cancer. Biomed. Pharmacother., 43, 661-667.
42. SCHLLTZ GS AND GRANT MB (1991). Neovascular growth factors. Eye, 5, 178-180.
43. SPORN MB, ROBERTS AB, WAKEFIELD LM, GLICK AB AND DANIELPOUR D. (1990). Transforming growth factor-beta and suppression of carcinogenesis. In Genetic Basis for Carcinogenesis: Tumour Suppression Genes and Oncogenes. Knudson Jr AG, Stanbridge EJ, Sugimura T, Terada M and Watanbe S. (eds) pp. 259 266. Japan Science Society Press: Tokyo; and Taylor and Francis: London.
44. STEWART HJ. (1989). Clinical experience in the use of the antioestrogen tamoxifen in the treatment of breast cancer. Proc. Royal. Soc. Edin., 95B, 231 237.
45. THOMPSON AM, KERR DJ AND STEEL CM. (1991). Transforming growth factor β1 is implicated in the failure of tamoxifen therapy. Br. J. Cancer, 63, 609 614.
46. TORRE-AMIONE G, BEAUCHAMP RD, KOEPPEN H, PARK BH, SCHREIBER H, MOSES HE AND ROWLEY DA. (1990). A highly immunogenic tumour transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci., USA, 1490.
47. TRAVERS MYT, BARRETT-LEE PJ, BERGER U, LUQMANI YA, GAZET, J-C, POWLES TJ AND COOMBES RC. (1988). Growth factor expression in normal, benign and malignant breast tissue. Br. Med. J., 296, 1621-1624.
48. 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur. J. Cancer, 28, 641-644.
49. 1 mRNA expression in breast carcinomas by in situ hybridization. J. Pathol., 177, 123-127.
50. WALKER RA, DEARING SJ AND GALLACHER B. (1994). Relationship of transforming growth factor β1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma. Br. J. Cancer, 69, 1160 1165.
51. WELCH DR, FABRA A AND NAKAJIMA M. (1990). Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc. Natl Acad. Sci. USA, 87, 7678-7682.